Details of the Drug Reposition

General Information of This Drug (ID: DMG9C4I)

Drug Name
Galidesivir   DMG9C4I
Synonyms 1EL1K52SH1; BCX 4430; BCX 4430 HCl; BCX4430; CS-3778; Galidesivir (hydrochloride); HY-18649; Immucillin-A; SB16943; SCHEMBL4838048; UNII-1EL1K52SH1
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Phase 1 [1]
------------------------------------------------------------------------------------
2 Preclinical Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Preclinical [2]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Preclinical [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03891420) A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19. U.S. National Institutes of Health.
2 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.